Global majors are trying to get into the high-growth vaccine market in India through standalone launches and alliances with local partners. Introduction of the National Immunisation Programme (NIP) and aggressive rollout of innovative products by domestic companies is prompting multinational corporations (MNCs) to strengthen presence in the India market. A McKinsey report on the Indian pharmaceutical
The steel sector was hit badly due to slowdown in infra projects, high interest rates and falling capex. Domestic steel prices were stable due to fall in supply from Karnataka region which accounts
Promise of large deals hit by high valuation expectations from Indian promoters and regulatory hurdles in the West.
The government wants to extend price control in pharmaceuticals. At the moment, prices of 74 bulk drugs are controlled by the government, which brings 300 or so formulations (combinations of bulk
Brand launches in the Indian pharmaceutical sector have dipped by more than half in 2011. On an average, pharma companies have launched 4,000 brands a year over the past four years but these have
Even as the government plans to amend the competition laws to enable the Competition Commission of India (CCI) to scrutinise all mergers and acquisitions (M&As) happening in Indian
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise